


IFW



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
JAMES E. COCKFIELD (1930-2005)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DEBRA J. MILASINCIC, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI

CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. MCKENNA
JAMES M. MCKENZIE
JILL R. GORNY
SAPNA MEHTANI, Ph.D.

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
BENEDICT A. MONACHINO

PATENT AGENTS
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK
JAMES H. VELEMA
JACOB G. WEINTRAUB
BRIAN C. TRINQUE, Ph.D.

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
MEAGHAN L. RICHMOND, Ph.D.
SHARON M. WALKER, Ph.D.
LAURA C. DILORENZO
ALISSA H. ENCK

* Admitted in TX only
** Admitted in CT only

October 7, 2005

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/619684
For: *METHODS FOR TREATING HORMONE ASSOCIATED CONDITIONS USING A
COMBINATION OF LHRH ANTAGONISTS AND SPECIFIC ESTROGEN
RECEPTOR MODULATORS*
Inventor: Garnick, Marc B.
Filed: July 14, 2003
Our Ref. No.: PPI-111

Dear Sir:


I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form SB/08;
3. Copies of selected publications cited in PTO Form SB/08 (6);
4. International Search Report; and
5. A Return Postcard.


No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on:

October 7, 2005
Date


Maria Laccotripe Zacharakis, Ph.D., J.D.
Reg. No. 56,266

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Maria Laccotripe Zacharakis, Ph.D., J.D.
Registration No. 56,266
Attorney for Applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Garnick, Marc B.

Serial No.: 10/619,684

Filed: July 14, 2003

For: *METHODS FOR TREATING HORMONE
ASSOCIATED CONDITIONS USING A
COMBINATION OF LHRH ANTAGONISTS AND
SPECIFIC ESTROGEN RECEPTOR MODULATORS*

Attorney Docket No.: PPI-111

Group Art Unit: 1646

Examiner: Not Yet Assigned

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

October 7, 2005

Date of Signature and of Mail Deposit

By:


Maria Laccotripe Zacharakis, Ph.D., J.D.
Registration No. 56,266
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicant and his Attorney are aware of the following publications and information, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. Reference ID Nos. A9, A17, A23, A28, and A29 were cited in an International Search Report dated May 8, 2003 during the prosecution of PCT/US02/00751 which corresponds to the above referenced application. Copies of cited U.S. patents and U.S. publications (Reference ID Nos. A1-A26) are not enclosed with this statement. Copies of foreign patent documents and non-patent literature (Reference ID Nos. A27-A29, B1-B3) are enclosed in accordance with 37 CFR 1.98(a)(2).

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP




Maria Laccotripe Zacharakis, Ph.D., J.D.
Registration No. 56,266
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: October 7, 2005

GAD/MLZ/DLN/krj
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/619684
				Filing Date	July 14, 2003
				First Named Inventor	Garnick, Marc B.
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PPI-111

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	4,418,068	11-29-1983	Jones	
	A2	4,431,635	02-14-1984	Coy <i>et al.</i>	
	A3	4,689,396	08-25-1987	Roeske <i>et al.</i>	
	A4	4,801,577	01-31-1989	Nestor, Jr. <i>et al.</i>	
	A5	4,851,385	07-25-1989	Roeske	
	A6	4,992,421	02-21-1991	De <i>et al.</i>	
	A7	5,003,011	03-26-1991	Coy <i>et al.</i>	
	A8	5,171,835	12-15-1992	Janaky <i>et al.</i>	
	A9	5,250,304	10-05-1996	Eskin <i>et al.</i>	
	A10	5,296,468	03-22-1994	Hoeger <i>et al.</i>	
	A11	5,300,492	04-05-1994	Haviv <i>et al.</i>	
	A12	5,371,070	12-06-1994	Koerber <i>et al.</i>	
	A13	5,393,763	02-28-1995	Black <i>et al.</i>	
	A14	5,413,990	05-09-1995	Haviv <i>et al.</i>	
	A15	5,470,947	11-28-1995	Folkers <i>et al.</i>	
	A16	5,811,415	09-22-1998	Cullinan <i>et al.</i>	
	A17	5,843,901	12-01-1998	Roeske	
	A18	5,843,984	12-01-1998	Clay <i>et al.</i>	
	A19	5,916,916	06-29-1999	Hauser <i>et al.</i>	
	A20	5,929,090	07-27-1999	Hauser <i>et al.</i>	
	A21	5,929,092	07-27-1999	Cullinan <i>et al.</i>	
	A22	5,962,475	10-05-1999	Schmid <i>et al.</i>	
	A23	5,968,895	10-19-1999	Gelter <i>et al.</i>	
	A24	5,994,370	11-30-1999	Bryant <i>et al.</i>	
	A25	6,147,092	11-14-2000	Cullinan <i>et al.</i>	
	A26	6,153,622	11-28-2000	Cameron <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	A27	WO 89/01944	03-09-1989	Board of Regents, University of Texas System		
	A28	EP 652 005 A1	05-10-1995	Eli Lilly and Company		
	A29	WO 97/27863	08-07-1997	Schering A.G. <i>et al.</i>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/619684
				Filing Date	July 14, 2003
				First Named Inventor	Garnick, Marc B.
				Art Unit	1646
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	PPI-111

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Guzzo, J.A. "Selective estrogen receptor modulators--a new age of estrogens in cardiovascular disease?" <i>Clin Cardiol.</i> 2000 Jan;23(1):15-7.	
	B2	Schaison G. "La GnRH et ses analogues – structure, mecanisme d'action et applications theapeutiques [GnRH and its analogs--structure, mechanism of action and therapeutic applications]" <i>J Steroid Biochem.</i> 1989 Oct;33(4B):795-9. French with English Abstract.	Abstr
	B3	Vickery, B.H. <i>et al.</i> , eds. <u>LHRH and its analogs : contraceptive and therapeutic applications</u> Boston, MTP Press, 1984-1987.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--